Ana I Fernandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8476412/publications.pdf

Version: 2024-02-01

687220 552653 29 694 13 26 citations h-index g-index papers 36 36 36 789 times ranked docs citations citing authors all docs

#	Article	IF	Citations
1	Co-amorphization of olanzapine for solubility enhancement. Annals of Medicine, 2024, 51, 87-87.	1.5	5
2	Drug-excipient and drug-drug mixtures: a pathway for the production of co-amorphous entities. Annals of Medicine, 2024, 51, 87-87.	1.5	2
3	A snapshot of anti-cellulite products' consumption and pharmaceutical intervention. Annals of Medicine, 2024, 51, 85-85.	1.5	2
4	Performance and paroxetine stability in tablets manufactured by fused deposition modelling-based 3D printing. Journal of Pharmacy and Pharmacology, 2022, 74, 67-76.	1.2	7
5	Polyvinyl alcohol/chitosan wound dressings loaded with antiseptics. International Journal of Pharmaceutics, 2021, 593, 120110.	2.6	43
6	Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction. Pharmaceutics, 2021, 13, 124.	2.0	13
7	Nutraceuticals for Smart Aging and Potential Drug Interactions. Medical Sciences Forum, 2021, 5, 4.	0.5	O
8	Tuning of Paroxetine 3D-Printable Formulations for Fused Deposition Modelling. Medical Sciences Forum, 2021, 5, 17.	0.5	2
9	Dispensing of Food Supplements in the Treatment and Prevention of Urinary Tract Infections. Medical Sciences Forum, 2021, 5, 1.	0.5	O
10	Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production. Medical Sciences Forum, 2021, 5, 2.	0.5	2
11	Coffee in the Workplace: A Social Break or a Performance Enhancer?. Medical Sciences Forum, 2021, 5, 44.	0.5	4
12	Influence of the Infill Geometry of 3D-Printed Tablets on Drug Dissolution. Medical Sciences Forum, 2021, 5, .	0.5	4
13	Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation. International Journal of Pharmaceutics, 2020, 588, 119716.	2.6	15
14	Polymer Selection for Hot-Melt Extrusion Coupled to Fused Deposition Modelling in Pharmaceutics. Pharmaceutics, 2020, 12, 795.	2.0	70
15	Quantification of theophylline or paracetamol in milk matrices by high-performance liquid chromatography. Journal of Pharmaceutical Analysis, 2017, 7, 401-405.	2.4	14
16	Production and characterization of spray-dried theophylline powders prepared from fresh milk for potential use in paediatrics. Journal of Pharmacy and Pharmacology, 2017, 69, 554-566.	1.2	3
17	Potentially inappropriate medications in a sample of Portuguese nursing home residents: Does the choice of screening tools matter?. International Journal of Clinical Pharmacy, 2016, 38, 1103-1111.	1.0	19
18	Evaluation of the ability of powdered milk to produce minitablets containing paracetamol for the paediatric population. Chemical Engineering Research and Design, 2016, 110, 171-182.	2.7	11

#	Article	IF	CITATIONS
19	Drug-Related Problems Identified in a Sample of Portuguese Institutionalised Elderly Patients and Pharmacists' Interventions to Improve Safety and Effectiveness of Medicines. Drugs - Real World Outcomes, 2016, 3, 89-97.	0.7	24
20	About the effect of eye blinking on drug release from pHEMA-based hydrogels: an <i>in vitro</i> study. Journal of Biomaterials Science, Polymer Edition, 2015, 26, 235-251.	1.9	21
21	Exploring a new jellyfish collagen in the production of microparticles for protein delivery. Journal of Microencapsulation, 2012, 29, 520-531.	1.2	39
22	Isolation and Biochemical Characterisation of a Novel Collagen from Catostylus tagi. Journal of Biomaterials Science, Polymer Edition, 2009, 20, 2073-2087.	1.9	35
23	The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. International Journal of Pharmaceutics, 2001, 217, 215-224.	2.6	109
24	Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cellular and Molecular Life Sciences, 2000, 57, 1964-1969.	2.4	77
25	Polysialic Acids: Potential Role in Therapeutic Constructs. Biotechnology and Genetic Engineering Reviews, 1999, 16, 203-216.	2.4	15
26	Polysialic Acids: Potential for Long Circulating Drug, Protein, Liposome and Other Microparticle Constructs., 1998,, 193-205.		1
27	Polysialylated asparaginase: preparation, activity and pharmacokinetics. BBA - Proteins and Proteomics, 1997, 1341, 26-34.	2.1	97
28	Synthesis, characterization and properties of sialylated catalase. BBA - Proteins and Proteomics, 1996, 1293, 90-96.	2.1	49
29	FC41 catalase-polysialic acid conjugates. European Journal of Pharmaceutical Sciences, 1994, 2, 111.	1.9	6